Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abstract Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments i...

ver descrição completa

Detalhes bibliográficos
Principais autores: RECOVERY Collaborative Group, Peter W. Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R. Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A. Green, Devesh J. Dhasmana, Flora Malein, Jaydip Majumdar, Paul Collini, Jack Shurmer, Bryan Yates, J. Kenneth Baillie, Maya H. Buch, Jeremy Day, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard Haynes, Martin J. Landray
Formato: Artigo
Idioma:English
Publicado em: Nature Portfolio 2024-01-01
coleção:Nature Communications
Acesso em linha:https://doi.org/10.1038/s41467-023-43644-x

Internet

https://doi.org/10.1038/s41467-023-43644-x

Registros relacionados